October 24, 2025: This is a space where we bring what actually moved in last 90 days.
From epi-on CXL to wrist-based hypertension alerts, here are the shifts that affect chair time, patient conversations, and referrals.
Eyecare – Major Development
1) FDA green-lights epi-on cross-linking for keratoconus (Glaukos Epioxa) – a less invasive alternative to epi-off CXL; launch targeted for early 2026. Clinical trials showed significant corneal shape improvement vs placebo. (Oct 2025)
Why it matters: shorter recovery, wider adoption potential for earlier KC stabilization.
2) Myopia control, spectacles edition, gets U.S. market authorization (Essilor Stellest) – first spectacle lens with FDA market authorization for slowing progression in kids 6-12 (Sep 2025).
Why it matters: expands beyond contacts/atropine; easier entry path for primary care ODs.
3) Premium IOL momentum in the U.S.
• BVI FineVision® HP trifocal IOL cleared (Oct 2025).
• Rayner RayOne EMV Toric approved (Oct 2025).
Two new U.S. approvals expand presbyopia/astigmatism options.
Why it matters: more presbyopia + astigmatism options; patient-reported outcomes and chair time will be key storylines.
4) Presbyopia drop commercialization ramps – LENZ VIZZ (FDA-cleared July) moving into broad HCP sampling and Q4 retail availability (Oct 2025).
Why it matters: expect patient inquiries; set expectations on onset/offset, near task benefits, and side effects.
5) AI screening speedups for Diabetic Retinopathy – “AI-powered retina tracker” presented at ENDO 2025 reports sub-second analysis with high accuracy (Jul 2025, Endocrine Society)
Why it matters: fuels point-of-care and retail/primary-care DR screening; watch for autonomous/assistive labeling and workflow fit.
6) Continuous/Near-continuous glaucoma monitoring – Wearable/implantable IOP sensors and “smart” lenses continue to show promise in recent conference and trade coverage (Jul-Sep 2025).
Why it matters: Prepare for data deluge; decide in advance who triages and what thresholds trigger action.
Broader Tech Shaping Health & Eye Care
7) Apple Watch adds “hypertension alerts” + Sleep Score (watchOS 26) – passive detection of patterns suggesting chronic high BP (requires new hardware/software; announced September 9). Independent reporting notes sensitivity caveats (~41%). (Sep 2025).
Why it matters: more patients will arrive with wrist-derived risk flags; ODs/PCPs should be ready with a confirmatory BP workflow. Counseling script: set expectations about false positives.
8) FDA keeps tightening the AI playbook – ongoing AI/ML device lifecycle guidance and a fresh request for public comment on real-world performance monitoring (Sep 2025).
Why it matters: if you’re evaluating AI tools (imaging, VF, coding, scribes), vendors’ monitoring/updates (PCCPs, drift detection) now matter as much as their AUROC.
9) Health-AI workforce up-skilling – Google Cloud + Adtalem announce an AI credential program for clinicians (Oct 2025).
Why it matters: rising baseline literacy will accelerate clinical adoption and patient expectations.
Plug & Play – Actions for coming weeks
- Keratoconus: Update your CXL referral sheet with an epi-on track and patient FAQ (pain, downtime, cost).
- Myopia: Add a “Spectacle-based control” column to your myopia protocol; train the front desk on parent FAQs.
- Premium IOLs: Refresh your co-management template (target, astigmatism plan, dysphotopsia counseling).
- Presbyopia drops: stay ahead of your patient query with a 1-page handout with candid onset/offset guidance and “who should skip.”
- AI DR screening: Decide your confirmatory pathway (OCT/retina referral) and billing flow before go-live.
- Hypertension alerts: Take glance at the patient’s wearable dashboard for red flag document counseling.
- Policy readiness: Add “AI monitoring” questions to any vendor RFP: real-world performance, update policy, audit logs.
Great article!